Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
Explore this paper's citation graph
Summary
The findings from an inception cohort of Medicare beneficiaries older than 65 years with state-sponsored prescription drug benefits are compatible with an increased risk of all-cause mortality and congestive heart failure in patients initiating therapy with rosiglitazone compared with similar patients initiate therapy with pioglitaz one.
- Type
- article
- Published
- 2008-11-24
- Cited by
- 123
- References
- 24
- OpenAlex
- https://openalex.org/W19029503
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24686872
Keywords
Philosophy
References
- Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
- Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
- Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
- Population-based studies of adverse drug effects.
- Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors
- The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
- Response to a comment on ‘the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy’
- Comparison of Coding of Heart Failure and Comorbidities in Administrative and Clinical Data for Use in Outcomes Research
- Cardiovascular risk and the thiazolidinediones: déjà vu all over again?
- Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.
- Coronary heart disease outcomes in patients receiving antidiabetic agents
- Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect.
- A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
- A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
- A meta-analysis of the association between adherence to drug therapy and mortality
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
- Evaluating medication effects outside of clinical trials: new-user designs.
- Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators
Cited by
- ６．RCT vs. Population-based Cohort Study：大規模な医療データの蓄積システムが必要
- Pharmacological modulation of insulin resistance : benefits and harms
- Innovations in Post-Marketing Safety Research
- Current and emerging strategies for treating dyslipidemia and macrovascular disease.
- Management and treatment of diabetes mellitus.
- The Comparative Effectiveness of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes
- Thiazolidinediones: a long way to clinical practice
- The rosiglitazone decision process at FDA and EMA. What should we learn?
- Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials.
- Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study
- Temporal trends in anti‐diabetes drug use in tricare following safety warnings in 2007 about rosiglitazone
- Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.
- Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
- Heart failure and new drugs: should we be aware?
- A PSO/ACO approach to knowledge discovery in a pharmacovigilance context
- Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
- Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
- Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications
- Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
- The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARγ, RORs, and Rev-erbs.
Related papers
No related papers recorded.